Wells Fargo has increased its price target for Willis Towers Watson (WTW) to $379.00 from $366.00 and kept an Overweight rating on the shares. The bank's revision follows quarterly results that displayed notable organic expansion, with investors responding positively to the company’s growth trajectory.
Drivers of the revision
Wells Fargo highlighted strong organic growth across Willis Towers Watson’s businesses, singling out the Risk & Broking (R&B) segment and, within it, the Corporate Risk & Broking (CRB) division. Management reported that CRB delivered 8% growth, while North America recorded high single-digit growth in the quarter compared with only 1% in the prior quarter. Those metrics were cited by Wells Fargo as a key reason the stock moved higher following the earnings release.
The bank noted that the outlook for the R&B segment calls for mid-single-digit to high-single-digit organic growth. According to Wells Fargo, that guidance was well received by investors and underpins the higher price target.
Analyst commentary on future performance
The Wells Fargo analyst emphasized that Willis Towers Watson’s shares should remain supported if the company is able to sustain the industry-leading organic growth implied in its 2026 guidance. The note specifically referenced the importance of achieving mid-single-digit to high-single-digit organic growth in the R&B segment for continued share-market outperformance.
Quarterly results and other analyst moves
Willis Towers Watson reported fourth-quarter 2025 earnings per share of $8.12, topping the analyst consensus of $7.96. Revenue for the quarter came in at $2.94 billion, above the expected $2.85 billion. These results were cited as being well received by the investment community.
In a separate update, Evercore ISI raised its price target on Willis Towers Watson to $390 from $383 and maintained an Outperform rating. Evercore highlighted the company’s strong performance and a constructive outlook for the Risk & Broking segment. The firm also noted that Willis Towers Watson has been able to outperform expectations despite headwinds in specialty lines, which it cited as a positive indicator of resilience.
Takeaway
Taken together, the price-target increases from Wells Fargo and Evercore ISI and the company’s quarterly beats reflect investor and analyst focus on sustained organic growth within R&B, especially CRB. Continued delivery against 2026 guidance appears central to future sentiment for the shares.